MENS - Jyong Biotech Limited Debt to Book Capitalization Ratio

Graphic logo of Jyong Biotech Limited (MENS)

Jyong Biotech Ltd (MENS) develops unique, patent-protected plant-based medicines, which minimizes direct competition. The popularity of preventive therapy in Asia is driving expanded demand for men's health products. Meanwhile, the business's success relies on passing tests, with the current metric standing at 0.00. The price chart below illustrates the dynamics of an asset whose survival depends on its ability to outperform industry behemoths in complex research.

MENS (Jyong Bio) Debt to Book Value history from 06/18/2025 to 10/28/2026
Core merchandise of Jyong Biotech Corp

This ratio measures the proportion of debt relative to equity, allowing for an assessment of financial leverage and default risk at the current value of 0.00. Analyzing the total debt-to-book capital of Jyong Biotech Ltd (MENS) is critical for stress testing, as prolonged clinical drug trials require stable funding that cannot be secured solely through the automation of drug synthesis.

Competitors of Jyong Biotech Ltd

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|LGND: Debt to Net Assets Ratio|AMRX (Amneal Pharmaceuticals Inc) - Debt to Book Capitalization Ratio|Perrigo Corp (PRGO) - Debt to Book Value|ALVO (Alvotech) - Debts to Book Capitalization|Debts to Book Capitalization liquidia.com (LQDA)|Galapagos (GLPG) - Debt to Book Value|Debt to Net Assets Ratio ANIP (ANI Pharmaceuticals Inc)|MNKD: Debt to Book Capitalization Ratio|AMPH - Debts to Book Value|Debt to Book Value Pacira BioSciences PCRX|SPRY - Debt to Book Capital|Debts to Book Capitalization Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Debt to Net Assets Ratio|Debts to Book Capitalization SCPH (scPharmaceuticals, Inc.)|Debts to Book Value TECX|Tonix Pharmaceuticals (TNXP) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio SXTC (sxtchina.com)|Debt to Book Capitalization Ratio Eupraxia Pharmaceuticals Inc. (EPRX)|BHST - Debt to Book Capital|EXOZ (Invizyne Technologies, Inc.) - Debt to Book Value|ORMP: Debts to Book Value|Debt to Book Capitalization Ratio ENTX|HYFT (ipatherapeutics.com) - Debts to Book Value|Debt to Book Capitalization Ratio ABVC BioPharma, Inc. (ABVC)|Debt to Book Value Ratio Cumberland Pharmaceuticals Inc|QNTM: Debts to Book Capitalization|Debt to Net Assets FibroGen Corporation FGEN|Debt to Book Value Telomir Pharmaceuticals|Debt to Net Assets Ratio Rani Therapeutics Holdings RANI|SNYR - Debts to Book Capitalization|RLYB - Debt to Book Capitalization Ratio|lexariabioscience.com - Debts to Book Capitalization|PULM (Pulmatrix Corporation) - Debts to Net Assets|Debt to Book Capitalization Ratio PTHL (Pheton Holdings Limited)|Debts to Book Value Aptorum (APM)|Debt to Book Value Lyra Therapeutics|Debt to Book Capital Impact BioMedical, Inc. (IBO)|TNFA: Debts to Book Capitalization|Debts to Book Value cbdMD Inc. YCBD|PRFX: Debts to Book Capitalization|CYTO - Debt to Book Value|Debts to Book Capitalization Lipella Pharmaceuticals, Inc. LIPO|Debt to Net Assets Ratio OptiNose Inc|PIRS - Debt to Book Value|Debt to Net Assets Ratio PROC|Debt to Book Capitalization Ratio Petros Pharmaceuticals (PTPI)|Debt to Book Capitalization Ratio qlsyy.net QLI|Debt to Book Value ACELYRIN (SLRN)|Debt to Book Capital TFF Pharmaceuticals Inc. TFFP